CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients

Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study

(2023) Emi Ishikawa et al.   INVESTIGATIONAL NEW DRUGS

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer

(2023) Yufeng Li et al.   Cell Communication and Signaling

Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

(2022) Thomas Rodier et al.   Pharmaceutics

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer

(2021) Luwei Han et al.   Frontiers in Pharmacology

An Evidence‐Based Framework for Evaluating Pharmacogenomics Knowledge for Personalized Medicine

(2021) Michelle Whirl‐Carrillo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015

(2021) Andrew G. Nicholson et al.   Journal of Thoracic Oncology

Polymorphisms of Drug-Metabolizing Enzymes and Transporters Contribute to the Individual Variations of Erlotinib Steady State Trough Concentration, Treatment Outcomes, and Adverse Reactions in Epidermal Growth Factor Receptor–Mutated Non-Small Cell Lung Cancer Patients

(2020) Dehua Liao et al.   Frontiers in Pharmacology

Influx and Efflux Transporters Contribute to the Increased Dermal Exposure to Active Metabolite of Regorafenib After Repeated Oral Administration in Mice

(2019) Aya Hasan Al-Shammari et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC

(2019) Suresh S. Ramalingam et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients

(2018) J Remon et al.   ANNALS OF ONCOLOGY

Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors

(2018) D Westover et al.   ANNALS OF ONCOLOGY

Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

(2018) Jean-Charles Soria et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib versus standard-of-care EGFR-TKI as first-line treatment in patients with EGFRm advanced NSCLC: FLAURA Asian subset

(2018) Byoung Chul Cho et al.   Journal of Thoracic Oncology

Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

(2017) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

(2016) Glenwood Goss et al.   LANCET ONCOLOGY

Association Study of a Functional Variant on ABCG2 Gene with Sunitinib-Induced Severe Adverse Drug Reaction

(2016) Siew-Kee Low et al.   PLoS One

The allele frequency of CYP2A6*4 in four ethnic groups of China

(2015) Cong Pang et al.   EXPERIMENTAL AND MOLECULAR PATHOLOGY

Which Genetic Determinants Should be Considered for Tacrolimus Dose Optimization in Kidney Transplantation? A Combined Analysis of Genes Affecting the CYP3A Locus

(2015) Henrike Bruckmueller et al.   THERAPEUTIC DRUG MONITORING

Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors

(2014) V. Hirsh et al.   Current Oncology

Association between CommonCYP1A2Polymorphisms and Theophylline Metabolism in Non-smoking Healthy Volunteers

(2013) Liqing Wang et al.   BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

(2012) Tomohiro Suzumura et al.   BMC CANCER

Plasma Letrozole Concentrations in Postmenopausal Women With Breast Cancer Are Associated With CYP2A6 Genetic Variants, Body Mass Index, and Age

(2011) Z Desta et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Induction of CYP1A2 by heavy coffee consumption is associated with the CYP1A2 −163C>A polymorphism

(2010) Natasa Djordjevic et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression

(2009) Pei-Chieng Cha et al.   JOURNAL OF HUMAN GENETICS

Clinical Significance of Skin Toxicity due to EGFR-Targeted Therapies

(2009) Monica Giovannini et al.   Journal of Oncology